LORD TRIAL

A randomised placebo controlled phase IV study to assess the effects of atorvastatin on the rate of decline of glomerular filtration rate in chronic kidney disease patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000693628

Acronym

LORD Trial

Enrollment

200

Registered

2005-10-28

Start date

2001-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

This is a three year study to determine the effect of an HMG-CoA reductase inhibitor on the progression of renal disease

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Chronic Kidney Disease, Serum Creatinine >130 umol for males and >120 umol for females.GFR< 60ml/min.

Exclusion criteria

Already taking a statinA seizure within a year of study entryHypersensitivity to atorvastatinParticipation or proposed participation in another clinical investigational study drug within 30 days.

Outcome results